Compare Amphastar Pharmaceuticals Inc (AMPH) vs ThredUp Inc (TDUP) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

ThredUp (TDUP) trades at $6.60, up 0.38% on the day, with a bullish technical signal and strong analyst support (57% buy ratings). The company reported Q1 2026 revenue of $81.7 million, a 15% year-over-year increase, and a gross margin of 79.2%, though net losses persist. Recent initiatives include launching a peer-to-peer marketplace and AI-driven shopping tools to boost growth.

The outlook is cautiously optimistic, with a consensus price target of $6.90 offering modest upside. Key opportunities lie in margin improvement and AI efficiency gains, but risks include sustained profitability challenges and competitive pressures in online resale. Investors should weigh growth potential against ongoing losses.